Navigation Links
Sangamo Announces Public Offering of Common Stock
Date:4/7/2011

gamo also has a Phase 1/2 clinical trial and two ongoing Phase 1 clinical trials to evaluate safety and clinical effect of a treatment for HIV/AIDS as well as a Phase 1 trial of a treatment for recurrent glioblastoma multiforme. Other therapeutic development programs are focused on Parkinson's disease, monogenic diseases, neuropathic pain and nerve regeneration.  Sangamo's core competencies enable the engineering of a class of DNA-binding proteins called zinc finger DNA-binding proteins (ZFPs).  By engineering ZFPs that recognize a specific DNA sequence Sangamo has created ZFP transcription factors (ZFP TFs) that can control gene expression and, consequently, cell function.  Sangamo is also developing sequence-specific ZFP Nucleases (ZFNs) for gene modification.  Sangamo has established strategic partnerships with companies in non-therapeutic applications of its technology including Dow AgroSciences and Sigma-Aldrich Corporation. For more information about Sangamo, visit the company's website at www.sangamo.com.

ZFP Therapeutic® is a registered trademark of Sangamo BioSciences, Inc.

This press release may contain forward-looking statements based on Sangamo's current expectations. These forward-looking statements include, without limitation, references to Sangamo's public offering of common stock, the anticipated timing of the closing of the offering, the research and development of novel ZFP TFs and ZFNs and therapeutic applications of Sangamo's ZFP technology platform. Actual results may differ materially from these forward-looking statements due to a number of factors, including, risks and uncertainties associated with market conditions and the satisfaction of customary closing conditions related to the proposed offering, technological challenges, Sangamo's ability to develop commercially viable products and technological developments by our competitors. See the company's SEC f
'/>"/>

SOURCE Sangamo BioSciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Sangamo BioSciences and CHDI Foundation Announce Collaboration to Develop ZFP Therapeutic® for Huntingtons Disease
2. Sangamo BioSciences Announces Presentation at the 10th Annual Needham Healthcare Conference
3. Sangamo BioSciences Reports Fourth Quarter and Full Year 2010 Financial Results
4. Sangamo BioSciences Announces Fourth Quarter and Full Year 2010 Conference Call and Webcast
5. Sangamo BioSciences Announces Presentation at J.P. Morgan Healthcare Conference
6. Sangamo BioSciences Announces Data Presentation of First In Vivo Demonstration of ZFN-mediated Gene Correction Via Systemic Delivery at American Society for Hematology Meeting
7. Sangamo BioSciences Awarded Grants for the Development of Four ZFP Therapeutic® Programs
8. Sangamo BioSciences Announces Third Quarter 2010 Conference Call and Webcast
9. Sangamo BioSciences Announces Presentation at Two Upcoming Investor Conferences
10. Sangamo BioSciences Announces Second Quarter 2010 Conference Call and Webcast
11. Sangamo BioSciences Announces Presentation at Two Upcoming Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... -- Axovant Sciences Ltd. (NYSE:  AXON), a leading clinical-stage biopharmaceutical ... presentations at three investor conferences: , Wednesday, September ... in New York at the New ... PM at the BioCentury NewsMakers Conference in New ... Center , Thursday, September 17 at 9:30 AM at ...
(Date:9/2/2015)... ... September 02, 2015 , ... The wet form of macular ... anti-vascular endothelial growth factor agents given by injection into the eye. Dry macular ... scientific protocol for the many millions diagnosed with it. AMD usually starts in ...
(Date:9/2/2015)... ... September 02, 2015 , ... ... botanical and plant-derived compounds. BCC Research reveals in its new report that ... this market defines the category and generates the most market demand. , ...
(Date:9/2/2015)... TEL-AVIV, Israel , September 2, 2015 /PRNewswire/ ... BLGTY, TASE: BOLT) ("BioLight" or the "Company"), a ... innovations in ophthalmology and cancer diagnostics, announced today ... treatment of glaucoma will be delivered at the ... of the European Society of Cataract & Refractive ...
Breaking Biology Technology:Axovant Sciences To Present At Upcoming Investor Conferences 2Axovant Sciences To Present At Upcoming Investor Conferences 3StemCell GeneticMed Announces That It Has Started Stem Cell Treatments for Age Related Dry Macular Degeneration (AMG) 2Plant-derived Compounds Poised to Assume Greater Role in Global Drug Markets, According to BCC Research 2Plant-derived Compounds Poised to Assume Greater Role in Global Drug Markets, According to BCC Research 3Presentations to Highlight BioLight's IOPtiMate[TM] System at Upcoming European Ophthalmology Conferences 2Presentations to Highlight BioLight's IOPtiMate[TM] System at Upcoming European Ophthalmology Conferences 3
... N.C. and ROCKVILLE, M.D., June 5 ,Laboratory ... LH ), one,of the world,s leading clinical ... Inc. (Nasdaq: VNDA ), a biopharmaceutical ... clinical-stage product,candidates for central nervous system disorders, ...
... Results of phase I/II study highlighted in oral presentation at ... ... Switzerland, June 5 At the 10th,International Conference on Malignant ... investigator-sponsored clinical trial of,Yttrium-90 Ibritumomab Tiuxetan (90Y-Zevalin) combined with the ...
... 4 Trubion Pharmaceuticals Inc.,(Nasdaq: TRBN ) ... vice president of research and development, is scheduled ... Biotechnology & Medical Technology,Conference on June 12 at ... at the,New York Palace Hotel in New York ...
Cached Biology Technology:LabCorp(R) and Vanda Pharmaceuticals Collaborate to Offer Genetic Tests 2LabCorp(R) and Vanda Pharmaceuticals Collaborate to Offer Genetic Tests 3LabCorp(R) and Vanda Pharmaceuticals Collaborate to Offer Genetic Tests 4LabCorp(R) and Vanda Pharmaceuticals Collaborate to Offer Genetic Tests 5Novel Investigational Regimen Combining Radiation Enhancing Agent With Ibritumomab Tiuxetan (Zevalin(R)) Produces High Rate of Complete Responses in Patients With Rituximab-Refractory Follicular Non-Hodgkin's Lymphoma 2Novel Investigational Regimen Combining Radiation Enhancing Agent With Ibritumomab Tiuxetan (Zevalin(R)) Produces High Rate of Complete Responses in Patients With Rituximab-Refractory Follicular Non-Hodgkin's Lymphoma 3Novel Investigational Regimen Combining Radiation Enhancing Agent With Ibritumomab Tiuxetan (Zevalin(R)) Produces High Rate of Complete Responses in Patients With Rituximab-Refractory Follicular Non-Hodgkin's Lymphoma 4Trubion Pharmaceuticals to Present at the 7th Annual Needham & Company Biotechnology & Medical Technology Conference 2
(Date:8/6/2015)... Aug. 6, 2015 Synaptics Inc. (NASDAQ: ... interface solutions, today announced collaboration with Microsoft on ... 10. Microsoft leveraged Synaptics, deep expertise in human ... Through stringent testing, Synaptics, advanced ... with Microsoft,s Precision TouchPad (PTP) specification empowering OEMs ...
(Date:8/4/2015)... DUBLIN , Aug. 04, 2015 /PRNewswire/ ... ( http://www.researchandmarkets.com/research/nvh7k2/digital_forensics ) has announced the addition ... Component (Hardware, Software, and Service), Sub-Segment (Computer ... Cloud Forensics), Tool Types, Service, Vertical and ... report to their offering. By ...
(Date:7/31/2015)... , 31 de julio de 2015 BGI llevará ... www.icg-10.org ) del 22 al 25 de octubre de ... La conferencia celebra su décimo aniversario este año. ... en una de las reuniones anuales más influyentes del ... una de las conferencias científicas más dinámicas, entusiastas y ...
Breaking Biology News(10 mins):Synaptics Chosen for Human Interface Co-Development on Windows 10 2Digital Forensics Market - The Market Represents a Compound Annual Growth Rate (CAGR) of 11.3% From 2015 to 2020 2La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 2La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 3
... the human gut adaptively shifts more than a quarter ... diet changes from sugar to complex carbohydrates. , This ... survive rapidly changing nutrient conditions but also helps maintain ... microbial society, according to researchers at Washington University School ...
... Inc. (Nasdaq: NGEN), developer of advanced diagnostic products, announced ... "Multiplexed Active Biologic Array" by the U.S. Patent and ... of addressing one or more electrodes (or "test sites") ... patent also covers a method for storing the value ...
... owners because of their vibrant colors. But those colors may ... For more than a century, biochemists have known that parrots ... of plumage colors, but their biochemical identity has remained elusive. ... behind the colors of parrots, describing on a molecular level ...
Cached Biology News:Highly adaptable genome in gut bacterium key to intestinal health 2Highly adaptable genome in gut bacterium key to intestinal health 3Nanogen Issued Patent for Electronic Microarray With Memory 2Transport System Smuggles Medicines Into Brain 2Transport System Smuggles Medicines Into Brain 3
... provides high-pressure tubing for use with ... chromatography systems. The kit includes precut ... PEEK tubing for the installation of ... running at flow rates less than ...
... 96 x 0.2 ml tubes or a ... a thumbwheel to adjust height and pressure ... cycling. Peltier heat pumps produce uniform, accurate ... of up to 1.4 degrees C per ...
... thermocycler provides maximum performance on minimum space. ... elements, high heating and cooling rates have ... times. With a maximum capacity of 48 ... the capacity of much more expensive 96 ...
Dual-bay Dyad thermal cycler chassis, does not include the Alpha units (requires 2)...
Biology Products: